IDEXX Laboratories, Inc. logo
IDEXX Laboratories, Inc. (IDXX)
Compare

IDEXX Laboratories, Inc. (IDXX) Operating Margin: 31.63%

Is IDEXX Laboratories, Inc.’s operating margin high or low?

IDEXX Laboratories, Inc.'s operating margin of 31.63% is 10% above its 5-year average of 28.64%, near the high end of its 5-year range (25.66%–31.60%).

The operating margin for IDEXX Laboratories, Inc. (IDXX) is 31.63% as of Wednesday, June 10, 2026. It is above its 12-month average by 4.48% (30.27%).

IDXX Operating Margin Chart

IDXX Operating Margin
31.60%+9.15% 1Y
Zoom

IDXX Average Operating Margin Chart

IDXX Current vs Average Operating Margin Chart

IDXX Operating Margin Metrics

OPERATING MARGIN

31.63%

OPERATING MARGIN AVG TTM

30.27%

OPERATING MARGIN AVG 3Y

29.30%

OPERATING MARGIN AVG 5Y

28.64%

OPERATING MARGIN AVG 10Y

25.13%

OPERATING MARGIN AVG 15Y

23.22%

OPERATING MARGIN AVG 20Y

21.69%

CURRENT VS TTM AVG

+4.48%

CURRENT VS 3Y AVG

+7.94%

CURRENT VS 5Y AVG

+10.43%

CURRENT VS 10Y AVG

+25.85%

CURRENT VS 15Y AVG

+36.22%

CURRENT VS 20Y AVG

+45.81%

IDXX Competitors' Operating Margin

NAMEMARKET CAPOPERATING MARGINTTM3Y5Y
IDEXX Laboratories, Inc. (IDXX)31.63%30.27%29.30%28.64%
Humana Inc. (HUM)$43.78B1.01%1.25%2.37%3.27%
Agilent Technologies, Inc. (A)$37.17B21.50%22.07%21.88%20.79%
Zoetis Inc. (ZTS)$34.20B37.57%37.33%36.70%36.14%
Centene Corporation (CNC)$31.94B-3.68%-0.98%0.21%0.84%
IQVIA Holdings Inc. (IQV)$30.60B13.86%14.15%13.50%11.74%
DexCom, Inc. (DXCM)$29.24B21.45%17.22%16.09%15.13%
Biogen Inc. (BIIB)$29.00B15.65%22.44%23.65%25.70%
Veeva Systems Inc. (VEEV)$26.73B28.79%26.93%23.33%24.40%
Regeneron Pharmaceuticals, Inc. (REGN)$62.59B24.32%26.52%32.61%38.03%

Operating Efficiency

Gross Margin

62.0%

Operating Margin

31.6%

IDEXX Laboratories, Inc. Operating Margin Formula & Definition

Operating Margin = Operating Income / Revenue

Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

IDEXX Laboratories, Inc. Operating Margin FAQ

What is the operating margin for IDEXX Laboratories, Inc. (IDXX)?
The operating margin for IDXX stock is 31.63%.
Is IDEXX Laboratories, Inc.'s operating margin high or low?
IDEXX Laboratories, Inc.'s operating margin of 31.63% is 10% above its 5-year average of 28.64%, near the high end of its 5-year range (25.66%–31.60%).
What is the TTM average operating margin for IDEXX Laboratories, Inc. (IDXX)?
The TTM average operating margin for IDXX stock is 30.27%.
What is the 3Y average operating margin for IDEXX Laboratories, Inc. (IDXX)?
The 3Y average operating margin for IDXX stock is 29.30%.
What is the 5Y average operating margin for IDEXX Laboratories, Inc. (IDXX)?
The 5Y average operating margin for IDXX stock is 28.64%.
What is the 10Y average operating margin for IDEXX Laboratories, Inc. (IDXX)?
The 10Y average operating margin for IDXX stock is 25.13%.
What is the 15Y average operating margin for IDEXX Laboratories, Inc. (IDXX)?
The 15Y average operating margin for IDXX stock is 23.22%.
What is the 20Y average operating margin for IDEXX Laboratories, Inc. (IDXX)?
The 20Y average operating margin for IDXX stock is 21.69%.

IDEXX Laboratories, Inc. Operating Margin History

DATEOPERATING MARGIN
2025-12-3131.60%
2024-12-3128.95%
2023-12-3129.97%
2022-12-3126.69%
2021-12-3128.99%
2020-12-3125.66%
2019-12-3122.97%
2018-12-3122.20%
2017-12-3120.98%
2016-12-3119.73%
2015-12-3118.72%
2014-12-3117.52%
2013-12-3119.37%
2012-12-3120.30%
2011-12-3119.38%
2010-12-3118.48%
2009-12-3117.06%
2008-12-3116.84%
2007-12-3114.76%
2006-12-3117.31%
2005-12-3118.07%
2004-12-3119.67%
2003-12-3116.89%
2002-12-3115.95%
2001-12-3114.65%
2000-12-3114.49%
1999-12-3113.14%
1998-12-319.10%
1997-12-31-1.67%
1996-12-3117.56%

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

Westbrook, ME
11,000 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Jonathan J. Mazelsky